Effects of edaravone dexborneol combined with rt-PA intravenous thrombolysis therapy on efficacy and prognosis of ultra-early acute cerebral infarction

doi:10.11958/20221607

Abstract

Abstract:

Objective To observe the efficacy and prognosis of edaravone dexborneol combined with intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) in the treatment of ultra-early acute cerebral infarction (ACI). Methods A total of 163 patients with ultra-early ACI were randomly divided into the combination group (treated with edaravone dexborneol combined with intravenous thrombolysis with rt-PA, n=78) and the control group (treated with intravenous thrombolysis with rt-PA, n=85). Therapeutic effects and changes of superoxide dismutase (SOD), reactive oxygen species (ROS), malondialdehyde (MDA), neuron-specific enolase (NSE), matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-12 (MMP-12), central nervous system-specific protein β (S100β), low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), creatine kinase (CK), creatine kinase isoenzyme (CK-MB), D-dimer (D-D), C-reactive protein (CRP), the National Institutes of Health Stroke Scale (NIHSS) scores, Modified Rankin Scale (mRS) scores and activity of daily living (ADL) scores were observed before and after treatment in the 2 groups. The fatality rate and the incidence of adverse reactions were compared between the two groups. Results After treatment, the total effective rate, SOD level and ADL score were higher in the combination group than those in the control group. Levels of ROS, MDA, NSE, MMP-9 and S100β, NIHSS score and mRS score were lower in the combination group than those in the control group (P<0.05). There were no significant differences in fatality rate and incidence of adverse reactions between the two groups (P>0.05). Conclusion Edaravone dexborneol combined with intravenous thrombolysis with rt-PA can improve the clinical effect in the treatment of patients with ultra-early ACI, and improve the prognosis.

Key words: brain infarction, drug therapy, combination, prognosis, edaravone and camphor, recombinant tissue plasminogen activator

CLC Number:

R743.33

Figures/Tables 7

References 21

[1]	LYU J, XIE Y, SUN M, et al. Clinical evidence and GRADE assessment for breviscapine injection (DengZhanHuaSu)in patients with acute cerebral infarction[J]. J Ethnopharmacol, 2020, 262(15):113137. doi:10.1016/j.jep.2020.113137.
[2]	泮露萍, 金皎蕾, 黄睿, 等. 经颅多普勒在急性脑梗死患者动脉内机械取栓后神经功能预后评估中的应用[J]. 中华危重病急救医学, 2020, 32(7):835-839.
	PAN L P, JIN J L, HUANG R, et al. Application of transcranial Doppler in prognosis assessment of nerve function in patients with acute cerebral infarction after intracranial mechanical thrombectomy[J]. Chin Crit Care Med, 2020, 32(7):835-839. doi:10.3760/cma.j.cn121430-20200410-00281.
[3]	DEGUCHI I, TANAHASHI N, TAKAO M. Clinical study of intravenous,low-dose recombinant tissue plasminogen activator for acute cerebral infarction:comparison of treatment within 3 hours versus 3-4.5 hours[J]. J Stroke Cerebrovasc Dis, 2018, 27(4):1033-1040. doi:10.1016/j.jstrokecerebrovasdis.2017.11.009.
[4]	刘前, 邓倩, 周静, 等. 依达拉奉右莰醇联合阿托伐他汀治疗老年急性脑梗死的临床疗效及对脑血流动力学的影响[J]. 中国老年学杂志, 2023, 43(2):276-279.
	LIU Q, DENG Q, ZHOU J, et al. Clinical efficacy of edaravone and camphor combined with atorvastatin in the treatment of acute cerebral infarction in the elderly and its effect on cerebral hemodynamics[J]. Chin J Gerontology, 2023, 43(2):276-279. doi:10.3969/j.issn.1005-9202.2022.02.006.
[5]	邹娜, 李聪灵, 常莉莎. 依达拉奉右莰醇对急性脑梗死的远期疗效及安全性研究进展[J]. 慢性病学杂志, 2022, 24(1):20-24.
	ZOU N, LI C L, CHANG L S. Research progress on the long-term efficacy and safety of edaravone dexborneol in the treatment of acute cerebral infarction[J]. Chron Pathematol J, 2022, 24(1):20-24. doi:10.16440/J.CNKI.1674-8166.2022.01.06.
[6]	蔡业峰, 贾真, 张新春, 等. 美国国立卫生院卒中量表(NIHSS)中文版多中心测评研究:附537例缺血中风多中心多时点临床测评研究[J]. 北京中医药大学学报, 2008, 31(7):494-498.
	CAI Y F, JIA Z, ZHANG X C, et al. Study on multi-center investigation of the Chinese version of National Institutes of Health Stroke Scale[J]. J Beijing Univ Tradit Chin Med, 2008, 31(7):494-498. doi:10.3321/j.issn:1006-2157.2008.07.017.
[7]	刘爱芹, 岳冬雪, 张津溶, 等. 不同mRS评分的急性缺血性脑卒中患者血清PTX3、GAL3、Npt水平[J]. 中国老年学杂志, 2021, 41(21):4617-4619.
	LIU A Q, YUE D X, ZHANG J R, et al. Serum levels of PTX3,GAL3 and Npt of acute ischemic stroke patients with different mRS scores[J]. Chin J Gerontol, 2021, 41(21):4617-4619. doi:10.3969/j.issn.1005-9202.2021.21.005.
[8]	秦芳, 王惠珍, 王静新, 等. 重症脑卒中患者日常生活活动能力调查分析[J]. 广东医学, 2012, 33(23):3627-3630.
	QIN F, WANG H Z, WANG J X, et al. Investigation and analysis of activities of daily living in patients with severe stroke[J]. Guang Dong Med J, 2012, 33(23):3627-3630. doi:10.3969/j.issn.1001-9448.2012.23.048.
[9]	谷亚伟, 楚旭, 赵岚, 等. 重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死伴应激性高血糖的临床研究[J]. 中华神经科杂志, 2022, 55(3):210-215.
	GU Y W, CHU X, ZHAO L, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke with high stress hyperglycemia[J]. Chin J Neurol, 2022, 55(3):210-215. doi:10.3760/cma.j.cn113694-20210907-00617.
[10]	孔令胜, 刘丽艳, 赵平, 等. 丁苯酞对时间窗3-4.5 h急性脑梗死rt-PA静脉溶栓后出血性转化的影响[J]. 中国医院药学杂志, 2020, 40(5):538-545.
	KONG L S, LIU L Y, ZHAO P, et al. Effect of butylphthalide on hemorrhagic transformation after intravenous thrombolysis of rt-PA in acute cerebral infarction with a time window of 3-4.5 h[J]. Chin J Hosp Pharm, 2020, 40(5):538-545. doi:10.13286/j.1001-5213.2020.05.13.
[11]	张留福, 席春华, 董斌, 等. 老年ACI患者rt-PA静脉溶栓治疗后的临床效果及预后影响因素[J]. 中国老年学杂志, 2021, 41(12):2472-2477.
	ZHANG L F, XI C H, DONG B, et al. Risk factors for clinical efficacy and prognosis of intravenous rt-PA treatment for aged ACI patients[J]. Chin J Gerontol, 2021, 41(12):2472-2477. doi:10.3969/j.issn.1005-9202.2021.12.004.
[12]	王倩倩, 刘斌, 郭娟. 依达拉奉右莰醇注射用浓溶液治疗急性脑梗死的疗效与安全性观察[J]. 中风与神经疾病杂志, 2022, 39(4):333-335.
	WANG Q Q, LIU B, GUO J. Efficacy and safety of edaravone dexcamphenol in the treatment of acute cerebral infarction[J]. J Apoplexy Nerv Dis, 2022, 39(4):333-335. doi:10.19845/j.cnki.zfysjjbzz.2022.0084.
[13]	姜飞, 王东玉. 依达拉奉右莰醇联合尿激酶静脉溶栓治疗急性脑梗死合并糖尿病对患者血清氧化应激水平、颈总动脉内-中膜厚度、血清基质金属蛋白酶-12水平的影响[J]. 陕西医学杂志, 2022, 51(1):88-91.
	JIANG F, WANG D Y. Effects of edaravone dexborneol combined with urokinase intravenous thrombolysis on serum oxidative stress,common carotid artery intra-media thickness and serum MMP-12 in patients with acute cerebral infarction and diabetes mellitus[J]. Shaanxi Med J, 2022, 51(1):88-91. doi:10.3969/j.issn.1000-7377.2022.01.023.
[14]	QURESHI A I, ASIF A, AYTAC E, et al. Preprocedure intravenous recombinant tissue plasminogen activator and risk of distal embolization with thrombectomy in acute ischemic stroke[J]. Journal of Stroke and Cerebrovascular Diseases, 2019:104362. doi:10.1016/j.jstrokecerebrovasdis.2019.104362.
[15]	杨丽亚, 张业敏, 葛伟, 等. rt-PA和尿激酶静脉溶栓治疗急性脑梗死安全性比较及对血栓弹力图的影响[J]. 中风与神经疾病杂志, 2022, 39(1):43-45.
	YANG L Y, ZHANG Y M, GE W, et al. Comparison of safety of intravenous thrombolytic therapy with rt-PA and urokinase in acute cerebral infarction and its effect on thromboelastogram[J]. J Apoplexy Nerv Dis, 2022, 39(1):43-45. doi:10.19845/j.cnki.zfysjjbzz.2022.0010.
[16]	王馨艺, 李静, 李雪, 等. 消瘀康胶囊对急性脑梗死患者血清MPO、CRP、ESR水平及临床疗效的影响[J]. 中国老年学杂志, 2020, 40(5):929-931.
	WANG X Y, LI J, LI X, et al. Effects of Xiaoyukang capsules on serum MPO,CRP,ESR levels and clinical efficacy in patients with acute cerebral infarction[J]. Chin J Gerontol, 2020, 40(5):929-931. doi:10.3969/j.issn.1005-9202.2020.05.012.
[17]	马冬娇, 陈国芳, 冯尧, 等. 依达拉奉右莰醇治疗早期急性进展性动脉粥样硬化型脑梗死的疗效[J]. 中国临床研究, 2022, 35(4):522-525.
	MA D J, CHEN G F, FENG Y, et al. Efficacy evaluation of edaravone dexborneol in the treatment of early acute progressive atherosclerotic cerebral infarction[J]. Chin J Clin Res, 2022, 35(4):522-525. doi:10.13429/j.cnki.cjcr.2022.04.016.
[18]	CHEN X, SUN Z, WANG J Q, et al. Predicting the pharmacokinetic characteristics of edaravone intravenous injection and sublingual tablet through modeling and simulation-sciencedirect[J]. Clin Ther, 2020, 42(3):428-438. doi:10.1016/j.clinthera.2020.01.006.
[19]	杨雪微, 施婵宏, 周金丽, 等. 早期应用依达拉奉右崁醇治疗经急诊血管内再灌注治疗后的急性缺血性卒中的临床疗效观察[J]. 实用药物与临床, 2022, 25(4):317-320.
	YANG X W, SHI C H, ZHOU J L, et al. Observation on clinical efficacy of early application of edaravone and dexborneol concentrated solution in the treatment of acute ischemic stroke after emergency intravascular reperfusion therapy[J]. Pract Pharm Clin Remed, 2022, 25(4):317-320. doi:10.14053/j.cnki.ppcr.202204006.
[20]	XU J, WANG A, MENG X, et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke:a phase III,randomized,double-blind,comparative trial[J]. Stroke, 2021, 52(3):772-780. doi:10.1161/STROKEAHA.120.031197.
[21]	张亚洁, 王炎强, 牟英峰, 等. 依达拉奉右莰醇对脑缺血再灌注大鼠焦虑抑郁样行为的影响及机制[J]. 中华行为医学与脑科学杂志, 2022, 31(1):17-24.
	ZHANG Y J, WANG Y Q, MOU Y F, et al. Effect of edaravone dexborneol on anxious-and depressive-like behaviors and its mechanism in rats with cerebral ischemia-reperfusion[J]. Chin J Behav Med Brain Sci, 2022, 31(1):17-24. doi:10.3760/cma.j.cn371468-20210602-00303.

组别	n	性别/ （男/女）	脑梗死部位
组别	n	性别/ （男/女）	脑叶	基底节	侧脑室	其他
对照组	85	51/34	21	39	23	2
联合用药组	78	49/29	17	36	21	4
χ²		0.136	1.000
组别	年龄/岁	发病至就诊时间/h	BMI/（kg/m²）
对照组	61.09±11.55	3.21±1.06	22.83±1.55
联合用药组	62.69±11.16	3.09±0.91	22.57±1.42
t	0.897	0.800	1.117

组别	n	性别/ （男/女）	脑梗死部位
组别	n	性别/ （男/女）	脑叶	基底节	侧脑室	其他
对照组	85	51/34	21	39	23	2
联合用药组	78	49/29	17	36	21	4
χ²		0.136	1.000
组别	年龄/岁	发病至就诊时间/h	BMI/（kg/m²）
对照组	61.09±11.55	3.21±1.06	22.83±1.55
联合用药组	62.69±11.16	3.09±0.91	22.57±1.42
t	0.897	0.800	1.117

组别	n	痊愈	显效	有效	无效	总有效率/%
对照组	85	18	36	13	18	67（78.82）
联合用药组	78	23	38	10	7	71（91.03）
Z或χ²		2.130^＊				4.664^＊

组别	n	痊愈	显效	有效	无效	总有效率/%
对照组	85	18	36	13	18	67（78.82）
联合用药组	78	23	38	10	7	71（91.03）
Z或χ²		2.130^＊				4.664^＊

组别		n	SOD/（U/mL）
组别		n	治疗前		治疗后	t
对照组		85	35.45±3.65		52.51±4.57	25.671^＊＊
联合用药组		78	34.23±4.85		64.21±6.38	34.045^＊＊
t			1.799		13.347^＊＊
组别	ROS/（μmol/L）
组别	治疗前			治疗后			t
对照组	640.17±65.15			518.47±53.68			13.364^＊＊
联合用药组	632.14±78.61			432.72±45.27			18.359^＊＊
t	0.707			10.974^＊＊
组别	MDA/（μmol/L）
组别	治疗前	治疗后	t
对照组	4.08±0.97	3.31±1.06	4.920^＊＊
联合用药组	4.07±1.04	1.29±0.78	19.530^＊＊
t	0.029	13.893^＊＊